Lewes, DE -- (SBWire) -- 08/07/2013 --LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Johnson & Johnson (NYSE:JNJ), Merck & Co., Inc. (NYSE:MRK), Bristol-Myers Squibb Co (NYSE:BMY), AbbVie Inc (NYSE:ABBV)

Johnson & Johnson (NYSE:JNJ) gained 0.07% recently, while trading on 6.80M shares at the price of $93.88. If we look at its trading history of the past 52 weeks, the share price suffered a low of $66.85 on Aug 30, 2012 and was moved to its maximum level of $94.42 on Jul 31, 2013. The stock changed hands in a range of $93.47 to $94.03, bringing its market capitalization at about $264.20B. Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field.

For How Long JNJ will Fight for Profitability? Read This Trend Analysis report

Merck & Co., Inc. (NYSE:MRK) added 0.33% recently, in the current trading session, at $48.60 with a total volume of 5.27M shares. The stock, on average, trades on a volume of 5.27M shares. In the past 52 weeks, the share price has not declined below $40.02 and above $50.16. It floated in a range of $48.35 to $48.75 during the recent trading session, with a beta value of 0.34. Its market capitalization now moved to about $146.87B. Merck & Co., Inc. (Merck) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.

For How Long MRK Gloss will Attract Investors? Find out via this report

Bristol-Myers Squibb Co (NYSE:BMY) recently recorded a fall of -0.79% and was moving within a range of $43.69 -$44.07. Its current trading price is $43.79. The share price hit its 52-week low of $30.64 on Nov 15, 2012 and $49.57 was the best price in the same period. The stock completed the day with a total volume of 2.89M shares, versus an average volume of 7.90M shares. Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.

Why Should Investors Buy BMY After the Recent Fall? Just Go Here and Find Out

AbbVie Inc (NYSE:ABBV) loss of -0.74% in its current trading activity, bringing its market capitalization around $70.59B. The total number of shares that changed hands during the current session up till now was 2.11M shares, as compared to average trading volume of 4.19M shares. The share price after opening at $44.70, made a high of $44.86 and hovered above $44.22, while its recent trading price was $44.55. AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. AbbVie's portfolio of products include a line of adult and pediatric pharmaceuticals, which includes HUMIRA.

Will ABBV Get Buyers Even After The Recent Rally? Find Out Here

About LeadingStockAlerts:

LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.

Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.
Disclaimer:
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/